Symposium "Mammaradiologie van Morgen"

Prof. Dr. C. van Gils

Resultaten van de DENSE trial: additionele MRI in het bevolkingsonderzoek bij vrouwen met zeer dichtborstweefsel.
In deze presentatie zal Prof. van Gils de uitkomsten van de DENSE trial bespreken en wat dit mogelijk kan betekenen voor het bevolkingsonderzoek borstkanker in de toekomst.

Dr. P.W.H. Hugen

Programmacoördinator Bevolkingsonderzoek Borstkanker RIVM-CvB (Centrum voor Bevolkingsonderzoek)

Patricia kijkt met ons naar de roep om invoering van innovaties in bevolkingsonderzoeken, waaronder tomosynthese in de borstkankerscreening. Is nieuw altijd beter? Houden we de regie? Kunnen we het nog uitleggen?

Drs. T. Rijken

Mia, herinneren of niet herinneren?

Prof. Dr. N. Karssemeijer

Beter screenen met AI

Prof. Dr. M. J. van den Hoven

Prof.dr. Marcel Jeroen van den Hoven – DUT/ Delft University of Technology
Jeroen van den Hoven is university professor and full professor of Ethics and Technology at Delft University of Technology. He is founding Editor in Chief of Ethics and Information Technology. He is Scientific director Delft Design for Values Institute.
He was the founding scientific director of 3TU.Centre for Ethics and Technology (2007-2013). In 2009, he won the World Technology Award for Ethics as well as the IFIP prize for ICT and Society for his work in Ethics and ICT. Jeroen van den Hoven was founder, and until 2016 Programme Chair, of the Dutch Research Council on Responsible Innovation. He is also member of the TU Delft Blockchain Lab.
In 2016 he is appointed at the European Advisory Group ‘Digital Ethics’. In 2017 he is appointed as a member of the European Group on Ethics in Science and New Technologies.
This year he published an article: Will Democracy Survive Big Data and Artificial Intelligence? in the Scientific American, an authoritave journal. He recently published his co-authored book “Evil Online”.

Prof. Jörg Heil

In patients with operable early breast cancer, neoadjuvant systemic treatment (NST) is a standard approach. Indications have expanded from downstaging of locally advanced breast cancer to facilitate breast conservation, to in vivo drug-sensitivity testing. The pattern of response to NST is used to tailor systemic and locoregional treatment, that is, to escalate treatment in non-responders and de-escalate treatment in responders. The talk will focus on 'response-adjusted' surgery of the breast after NST and discuss on how can we assess response with the least morbidity and best accuracy possible. Moreover we must have in mind what oncological consequences may ensue if we rely on a nonsurgical-generated diagnosis of, for example, minimally invasive biopsy proven pCR, knowing that we may miss minimal residual disease in some cases.

Drs. B.M. den Dekker

Geavanceerde biopsie systemen leveren steeds grotere biopten en bieden real-time verificatie met directe röntgenopnames van ieder biopt. Hoeveel biopten zijn voldoende om tot de diagnose te komen? En bent u klaar zodra er kalk is gebiopteerd? Bianca den Dekker, arts-onderzoeker UMCU, onderzocht de diagnostische waarde van opeenvolgende biopten bij 120 vrouwen die een stereotactische biopsie ondergingen met het 9-gauge Brevera biopsie systeem.

Prof. Dr. J.J.W. Lagendijk

Kan de MR-versneller gebruikt worden bij de radiotherapie van patiënten met borstkanker?

Prof. dr. L. M. Verkooijen